Stephens Reaffirms “Overweight” Rating for Delcath Systems (NASDAQ:DCTH)

Stephens restated their overweight rating on shares of Delcath Systems (NASDAQ:DCTHFree Report) in a report released on Monday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

DCTH has been the topic of several other research reports. Wall Street Zen downgraded Delcath Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective (up previously from $24.00) on shares of Delcath Systems in a research report on Friday, May 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $24.00.

View Our Latest Analysis on Delcath Systems

Delcath Systems Stock Down 4.3%

DCTH stock opened at $13.26 on Monday. The firm has a market cap of $461.79 million, a PE ratio of -26.52 and a beta of 0.95. The business has a 50 day moving average of $14.46 and a 200-day moving average of $13.73. Delcath Systems has a 12-month low of $7.17 and a 12-month high of $18.23.

Delcath Systems (NASDAQ:DCTHGet Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. The firm had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. On average, research analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

A number of large investors have recently added to or reduced their stakes in DCTH. Jefferies Financial Group Inc. bought a new position in shares of Delcath Systems during the fourth quarter valued at about $251,000. Principal Financial Group Inc. grew its stake in shares of Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock worth $1,387,000 after purchasing an additional 25,736 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Delcath Systems in the fourth quarter worth about $153,000. Jane Street Group LLC grew its stake in shares of Delcath Systems by 1,364.6% in the fourth quarter. Jane Street Group LLC now owns 178,797 shares of the company’s stock worth $2,153,000 after purchasing an additional 166,589 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Delcath Systems by 1,816.5% in the fourth quarter. Bank of America Corp DE now owns 25,700 shares of the company’s stock worth $309,000 after buying an additional 24,359 shares during the period. Hedge funds and other institutional investors own 61.12% of the company’s stock.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Further Reading

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.